Mirror replication is delayed on 2 of 3 tables. Showing last replicated data. Data may be stale.

Public note

For situational awareness and research transparency. Not medical advice.

Novel Pathogen Detectionactive

CDC 2026 AR Threats Report (electronic release) will document that ≥3 of the 6 hospital-onset AMR pathogen groups tracked in the 2024 special report (CRAB, CRE, ESBL-Ent, MRSA, MDR-Pa, VRE) remain ≥10% above pre-pandemic 2019 baseline through 2024 surveillance data, confirming sustained post-COVID AMR backslide rather than recovery.

System-generated assessment. This assessment remains under review until the stated horizon or until sufficient evidence allows evaluation.

Substantial confidence

Confidence in this assessment

70%

Multiple lines of evidence are aligned, though the assessment remains provisional. Based on 23 linked evidence items and assessed against Dec 31, 2026.

Assessed through Dec 31, 202623 linked evidence itemsTracking since Apr 20, 2026

How this assessment will be evaluated

The criteria the system uses to determine whether this assessment is borne out by the stated horizon.

Automated

Method

Evidence Match

The condition the system checks for when evaluating this assessment.

Minimum source quality

T1Primary Institutional

Evidence must meet or exceed this credibility tier to count toward evaluation.

Required terms

hospital-onsetpre-pandemicsurveillanceelectronic

Evidence quality mix

Tracking since Apr 20, 2026.

T112

T211

Integrity referencesCryptographic hashes for verification

Registration

Integrity anchor

Brier 0.210

17 resolved novel pathogen detection predictions.

Scope synthesis

The current analyst narrative for this scope.

Open synthesis →

AMR evidence pipeline severely constrained this cycle; two hypotheses resolve Apr 27 without confirmatory data; PubMed failure and stale secondary connectors limit incident coverage.

CDC AR Threats Report not yet released; hypothesis open

Evidence linked to this assessment

23 linked items.

Global Antimicrobial Resistance and Use Surveillance System (GLASS). Coronavirus disease (COVID-

Currently interpreted as supporting evidence for 7 tracked assessments.

T1https://www.who.int/initiatives/glasssupports

Apr 20, 2026

Global Antimicrobial Resistance and Use Surveillance System (GLASS). Newsroom Newsroom News rele

Currently interpreted as supporting evidence for 7 tracked assessments.

T1https://www.who.int/initiatives/glasssupports